---
layout: entry
title: "A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19"
link: "https://doi.org/10.1016/j.msard.2020.102182"
author:
- Valencia-Sanchez, Cristina; Wingerchuk, Dean M.

summary:
- "treatment decisions in patients with multiple sclerosis are challenging. It is not known whether and how various disease modifying therapies affect COVID-19 risk and disease course. A brief course of tocilizumab for the treatment may be effective while not aggravating pre-existing MS. The coronavirus disease 2019 (COVID19) pandemic is challenging, not known. Treatment decisions are challenging, but it is unclear if and how diverse disease. therapies, especially immunosuppressive drugs, affects."

original:
- "Treatment decisions in patients with multiple sclerosis (MS) during the coronavirus disease 2019 (COVID-19) pandemic are challenging. It is not known whether and how various disease modifying therapies, especially immunosuppressive drugs, affect COVID-19 risk and disease course. Methods : Case report Results : We report a fingolimod-treated MS patient who developed severe COVID-19 but recovered after treatment with tocilizumab. Conclusion : This report suggests that a brief course of tocilizumab for the treatment of severe COVID-19 may be effective while not aggravating pre-existing MS."
---

